ReviewInternational journal of oncology2024
Current development of molecular classifications of gastric cancer based on omics (Review).
Review in International journal of oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular targets and mechanisms of traditional Chinese medicine combined with chemotherapy for gastric cancer: a meta-analysis and multi-omics approach.Annals of medicine · 2025Pooled it
- Role of CMTM6 in disease pathogenesis and clinical translation potential (Review).Molecular medicine reports · 2026Review
- Advances in Gastric Cancer Research: Insights Into Carcinogenesis, the Tumor Microenvironment, Metastasis, and Factors Influencing Prognosis.Annals of gastroenterological surgery · 2026Review
- Liquid-liquid phase separation-related gene signature characterizes prognostic subtypes and therapeutic sensitivities in gastric cancer.Translational cancer research · 2026Article
- Advances in the molecular subtyping of gastric cancer.World journal of surgical oncology · 2026Review
- Progastricsin (Pepsinogen C) is downregulated in gastric adenocarcinoma: evidence from a South Asian population.BMC cancer · 2026Observational
- Analysis of the clinical diagnostic efficacy of the novel serum markers lipase F, gastrokine 2 and the collagen X-type α1 chain in gastric cancer.Journal of medical biochemistry · 2026Article
- Natural Products Targeting Key Molecular Hallmarks in Gastric Cancer: Focus on Apoptosis, Inflammation, and Chemoresistance.International journal of molecular sciences · 2026Review
- Spatial omics and its applications for a tumour microenvironment characterization and precision medicine approach of gastric cancer.Ecancermedicalscience · 2026Review
- Integrated multi-omics and machine learning identify EFNA3 as a key biomarker of tumor invasion.Frontiers in immunology · 2026Article
- Hippo-YAP/TAZ signaling in gastric cancer: orchestrating epithelial-stromal heterogeneity, plasticity, and therapy resistance.Cancer heterogeneity and plasticity · 2026Article
- Spatially resolved endothelial signaling via nampt-itga5 drives immune evasion in stem-like gastric cancer.Cancer immunology, immunotherapy : CII · 2025Article
- Study on the regulation of gastric cancer cell apoptosis by LACTB through mitochondrial autophagy pathway.Scientific reports · 2025Article
- Traditional Chinese medicine and modern technology: Network pharmacology and omics sequencing in gastric cancer.World journal of gastrointestinal oncology · 2025Article
- COL1A1, COL1A2, CHN1, and FN1 Promote Tumorogenesis and Act as Markers of Diagnosis and Survival in Gastric Cancer Patients.Current pharmaceutical biotechnology · 2025Article
- The Role of UFMylation in the Development and Progression of Gastric Cancer.Oncology research · 2025Review
- Metabolomic profiling of childhood medulloblastoma: contributions and relevance to diagnosis and molecular subtyping.Journal of cancer research and clinical oncology · 2024Review
- A New Medical Evaluation for Gastric Cancer Patients to Increase the Success Rate of Immunotherapy: A 2024 Update.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Risk Prediction Models for Gastric Cancer: A Scoping Review.Journal of multidisciplinary healthcare · 2024Article
- [Insights into the occurrence and heterogeneity of gastric cancer from the perspective of clinical data integration].Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is a complex and heterogeneous disease with significant phenotypic and genetic variation. Traditional classification systems rely mainly on the evaluation of clinical pathological features and conventional biomarkers and might not capture the diverse clinical processes of individual GCs. The latest discoveries in omics technologies such as next‑generation sequencing, proteomics and metabolomics have provided crucial insights into potential genetic alterations and biological events in GC. Clustering strategies for identifying subtypes of GC might offer new tools for improving GC treatment and clinical trial outcomes by enabling the development of therapies tailored to specific subtypes. However, the feasibility and therapeutic significance of implementing molecular classifications of GC in clinical practice need to addressed. The present review examines the current molecular classifications, delineates the prevailing landscape of clinically relevant molecular features, analyzes their correlations with traditional GC classifications, and discusses potential clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.